Publications
The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs
Shashank R Joshi, Rajesh Rajput, Subhankar Chowdhury, Awadhesh K Singh , Ganapathi Bantwal, Ashok K Das, A G Unnikrishnan , Banshi D Saboo , Jothydev Kesavadev, Samit Ghosal, Viswanathan Mohan Abstract
Aims: Despite their established benefits, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remain underutilized for type 2 diabetes mellitus (T2DM) management, which indicates that subcutaneous injection is an unfavorable mode of delivery from the patient's perspective. This review summarizes existing challenges related to medication adherence and the use of antihyperglycemia injectables, revisits the established safety and efficacy of oral semaglutide, and explores its features and considerations for use among the Indian T2DM population.
Methods: We performed a literature search using MEDLINE and the National Institutes of Health Clinical Trials Registry from July 1, 2016, to July 1, 2021, to identify publications on oral semaglutide approval, T2DM treatment guidelines, and clinical evidence for oral drug formulation.
